SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3β/β-Catenin Signaling Axis

Resistance to temozolomide (TMZ), the standard chemotherapy agent for glioblastoma (GBM), poses a major clinical challenge to GBM prognosis. Understanding the mechanisms of TMZ resistance can help to identify novel drug targets and more effective therapies. Recent studies suggest that bioenergetic a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Pharmacol
Main Authors: Dai, Shuang, Yan, Yuanliang, Xu, Zhijie, Zeng, Shuangshuang, Qian, Long, Huo, Lei, Li, Xuejun, Sun, Lunquan, Gong, Zhicheng
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2018
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5758607/
https://ncbi.nlm.nih.gov/pubmed/29354058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00960
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados